NEUROCRINE BIOSCIENCES INC (NBIX) Stock Price, Quote, News and Overview
NASDAQ:NBIX - Nasdaq - US64125C1099 - Common Stock - Currency: USD
NBIX Quote, Performance and Key Statistics
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (2/4/2025, 8:00:01 PM)
After market: 152.42 0 (0%)152.42
+2.32 (+1.55%)
The current stock price of NBIX is 152.42 USD. In the past month the price increased by 10.37%. In the past year, price increased by 15.21%.
NBIX Latest News, Press Releases and Analysis
NASDAQ:NBIX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
NEUROCRINE BIOSCIENCES INC may be an undervalued stock option. NASDAQ:NBIX retains a strong financial foundation and an attractive price tag.
Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
/PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results...
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational study to evaluate the efficacy, safety...
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator...
NBIX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About NBIX
Company Profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,700 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Company Info
NEUROCRINE BIOSCIENCES INC
6027 Edgewood Bend Court
San Diego CALIFORNIA 92130 US
CEO: Kevin C. Gorman
Employees: 1700
Company Website: https://www.neurocrine.com/
Investor Relations: https://neurocrine.gcs-web.com/
Phone: 18586177600
NBIX FAQ
What is the stock price of NBIX?
The current stock price of NBIX is 152.42 USD.
What is the symbol for NEUROCRINE BIOSCIENCES INC stock?
The exchange symbol of NEUROCRINE BIOSCIENCES INC is NBIX and it is listed on the Nasdaq exchange.
On which exchange is NBIX stock listed?
NBIX stock is listed on the Nasdaq exchange.
Is NBIX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NBIX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NBIX.
Does NBIX stock pay dividends?
NBIX does not pay a dividend.
When does NBIX stock report earnings?
NBIX will report earnings on 2025-02-11, after the market close.
What is the Price/Earnings (PE) ratio of NBIX?
The PE ratio for NBIX is 40.86. This is based on the reported non-GAAP earnings per share of 3.73 and the current share price of 152.42 USD.
What is the Short Interest ratio of NBIX stock?
The outstanding short interest for NBIX is 3.21% of its float.
NBIX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NBIX. When comparing the yearly performance of all stocks, NBIX is one of the better performing stocks in the market, outperforming 82.76% of all stocks.
NBIX Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to NBIX. NBIX scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
NBIX Financial Highlights
Over the last trailing twelve months NBIX reported a non-GAAP Earnings per Share(EPS) of 3.73. The EPS increased by 100.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.21% | ||
| ROA | 10.92% | ||
| ROE | 14.19% | ||
| Debt/Equity | 0 |
NBIX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to NBIX. The Buy consensus is the average rating of analysts ratings from 33 analysts.
For the next year, analysts expect an EPS growth of 70.21% and a revenue growth 24.55% for NBIX